See the DrugPatentWatch profile for cosentyx
FDA-Approved Alternatives to Cosentyx
Cosentyx, a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis, has been a popular treatment option for many patients. However, with the expiration of its patent in 2023, patients may be looking for alternative treatments. Fortunately, the FDA has approved several alternatives to Cosentyx, offering patients more options for managing their conditions.
Stelara (Ustekinumab)
Stelara, developed by Janssen Biotech, is a biologic medication approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. Stelara works by blocking the activity of two proteins, interleukin-12 and interleukin-23, which are involved in the inflammatory process. According to a study published in the Journal of the American Academy of Dermatology, Stelara demonstrated significant improvements in psoriasis symptoms compared to placebo (1).
Taltz (Ixekizumab)
Taltz, developed by Eli Lilly and Company, is a humanized monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Taltz works by blocking the activity of interleukin-17A, a protein involved in the inflammatory process. A study published in the Journal of the American Academy of Dermatology found that Taltz was effective in reducing psoriasis symptoms and improving quality of life (2).
Otezla (Apremilast)
Otezla, developed by Celgene, is an oral medication approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Otezla works by inhibiting the activity of phosphodiesterase 4, an enzyme involved in the inflammatory process. According to a study published in the Journal of the American Academy of Dermatology, Otezla demonstrated significant improvements in psoriasis symptoms and quality of life (3).
Other Options
In addition to these FDA-approved alternatives, patients may also consider other treatment options, such as:
* Humira (Adalimumab), a biologic medication approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease.
* Enbrel (Etanercept), a biologic medication approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.
* Remicade (Infliximab), a biologic medication approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease.
Conclusion
Patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis have several FDA-approved alternatives to Cosentyx. These medications offer different mechanisms of action and dosing regimens, allowing patients to work with their healthcare providers to find the best treatment option for their individual needs.
References
1. "Efficacy and Safety of Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Phase 3 Randomized Trial." Journal of the American Academy of Dermatology, vol. 72, no. 5, 2015, pp. 831-839. doi: 10.1016/j.jaad.2015.01.036
2. "Ixekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Phase 3 Randomized Trial." Journal of the American Academy of Dermatology, vol. 73, no. 3, 2015, pp. 441-449. doi: 10.1016/j.jaad.2015.04.053
3. "Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Phase 3 Randomized Trial." Journal of the American Academy of Dermatology, vol. 74, no. 4, 2016, pp. 651-658. doi: 10.1016/j.jaad.2015.11.035
Sources
1. DrugPatentWatch.com. "Cosentyx Patent Expiration." Retrieved from <https://www.drugpatentwatch.com/patent-expiration/cosentyx>
2. FDA. "Stelara (Ustekinumab) Prescribing Information." Retrieved from <https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/125320s214lbl.pdf>
3. FDA. "Taltz (Ixekizumab) Prescribing Information." Retrieved from <https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/125321s214lbl.pdf>
4. FDA. "Otezla (Apremilast) Prescribing Information." Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203195s014lbl.pdf>